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ABSTRACT 
Benzodiazepines (BDZs) represent first line treatment for the acute management of epileptic 
seizures and status epilepticus. The emergency use of BDZs requires timely administration 
and considering that most seizures occur outside of the hospital, there is a significant need for 
easy to use delivery methods that can be given quickly and safely by nonclinical caregivers.  
In addition, the ideal route of administration should be reliable in terms of absorption. In the 
US, rectal diazepam is the only licensed formulation, while in the EU rectal diazepam and 
buccal midazolam are currently licensed. However, both the rectal and buccal administration 
are not ideal as the absorption can be sometimes unpredictable. Several alternative routes are 
being explored and are currently under investigation. This is a narrative review of available 
data about delivery methods for BDZs alternative to the intravenous and oral routes for the 
acute treatment of seizures. Unconventional delivery options such as the direct delivery in the 
central nervous system or inhalers are reported. Available data shows that intranasal 
diazepam or midazolam and the intramuscular auto-injector for midazolam are as effective as 
rectal or intravenous diazepam. Head to head comparisons with buccal midazolam are 
urgently needed. In addition, the majority of trials focused on children and adolescents and 
further trials in adults are warranted.   
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1. Introduction 
Benzodiazepines (BDZs) remain first-line agents for the acute management of 
convulsive seizures and status epilepticus [1,2] while their use in the long-term prophylactic 
treatment of epilepsy has been historically limited by two major problems: side-effects, 
especially sedation, and the high potential for tolerance [3]. According to the NICE 
guidelines, children, young people and adults with epilepsy should receive emergency care in 
case of prolonged (lasting more than 5 minutes) or repeated (three or more in an hour) 
convulsive seizures [4]. Diazepam (DZP), lorazepam (LZP) and midazolam (MDZ) are the 
most widely used drugs in both adults and children. They have different pharmacokinetic 
profiles [5,6] and are available in different pharmacological formulations [1,7] (Table 1). For 
many years, rectal diazepam has been a very popular rescue medication and still represents 
the only out of hospital treatment approved in the US, but this rout of administration is 
problematic and most of the time socially unacceptable, especially in adults [8]. In the EU, 
buccal midazolam is also licensed for this indication and is now a widely used treatment in 
the community for patients with prolonged or repeated convulsive seizures. However, this 
rout is also not ideal as the absorption can still be unpredictable and if the drug is swallowed, 
it will then be subjected to metabolism and first-pass effect (Table 2). 
The emergency use of BDZs requires timely administration and considering that most 
seizures occur outside of the hospital, there is a significant need for easy to use delivery 
methods that can be given quickly and safely by nonclinical caregivers at home, school, work 
or any institution. In fact, initiating an IV infusion system can be challenging, requiring 
specially trained and competent personnel as well as various supplies. At the moment, several 
alternative routes are being explored and are currently under investigation. This is a narrative 
review of available data about non-intravenous delivery methods for BDZs in the acute 
treatment of seizures. References have been identified through Medline searches until June 
2016 using the terms “epilepsy”, “benzodiazepines”, “acute repeated seizures”, “status 
epilepticus”, “clinical trial”. Additional publications were hand searched if relevant for the 
discussion. 
 
2. Intranasal delivery 
There are three distinct functional areas in the nasal cavity: the vestibular, olfactory 
and respiratory zones. Due to the rich vascularization, the olfactory and in particular the 
respiratory zone, with a total surface of approximately 145 cm2, may serve as an efficient 
absorption surface for topically applied drugs [9]. The intranasal administration of BDZs 
became rapidly attractive because the nasal cavity is easily accessible and the nasal 
absorption is not subjected to the hepatic first-pass effect [10][11]. In addition, the absorption 
through the cribriform plate can lead to a rapid increase in drug concentrations in the CSF as 
compared to other delivery methods and this is obviously crucial for a brain disorder like 
epilepsy [12]. However, the intranasal administration is limited by a number of factors: i) the 
extent of the nasal mucosa; ii) blood flow of the nasal mucosa; iii) potential mechanical drug 
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loss anteriorly and posteriorly (Table 2). For all these reasons, the delivering technology 
becomes crucial for an effective absorption. In fact, in case of liquid formulations or drops, 
the head of the patient should be maintained in a specific position in order not to lose the drug 
in the throat or outside the nasal cavity (i.e. the patient should be turned on back with head 
slightly hyperextended, if in wheelchair head back hyperextended). It is evident that this is 
not always possible during a convulsion especially if prolonged. For this reason spray or 
atomised pumps have been developed in order to reach the best mucosal distribution.    
Clinical studies on the use of intranasal BDZs for the acute management of seizures are 
available for MDZ [13–22] and LZP [23,24] suggesting that, in both cases, the intranasal 
delivery is a potentially efficient alternative root of administration (Table 3) and ad hoc 
technologies are currently under investigation. In particular, there are two intranasal DZP 
formulations currently under development by Neurelis (10 mg) and Acorda Therapeutics (20 
mg) and a MDZ intranasal formulation by Upsher-Smith Laboratories (2.5 mg, 5 mg, 7.5 mg) 
[10]. Intranasal MDZ is the one at the more advanced stage as it is already under Phase III 
while DZP studies are still in Phase I for Neurelis and Phase II for Acorda [10]. 
Pharmacokinetic data showed that absorption is more reliable and efficient than using the 
injectable solution but data in patients with epilepsy in “real life” settings are still lacking. 
A number of trials compared intranasal MDZ with either rectal DZP or intravenous DZP [13-
22] (Table 3). Available data suggests that intranasal MDZ is effective, safe and more 
efficient that rectal DZP in controlling seizure activity [7] (Table 3). In general terms, as 
compared to DZP, MDZ has the advantage of a faster absorption but the lower bioavailability 
and the shorter half-life may be potentially associated with an increased risk of recurrence 
[10]. Future studies comparing purpose-developed intranasal formulations of MDZ will be of 
interest. 
Data about intranasal LZP are limited to two studies (Table 3) showing similar efficacy as 
compared to paraldehyde [24] and intravenous LZP [23]. However, paraldehyde is not a 
useful comparator as it is not generally considered first line agent and LZP is less lipophilic 
than MDZ, making it not ideal for intranasal delivery.  
 
3. Buccal delivery 
The buccal administration is another transmucosal route like the intranasal and rectal 
ones. It is, therefore, characterised by the same advantages such as a rapid absorption and no 
first-pass effect (Table 2). In addition, it has the advantage of an easier administration as 
compared to the intranasal and rectal roots.  However, it is usually more suitable for drugs 
administered at small doses because if any part of the dose is swallowed that proportion 
should be treated as an oral dose and subject to liver metabolism (Table 2). MDZ is the most 
popular buccal formulation and has been investigated in a number of clinical trials [25–33], 
demonstrating to be more effective than rectal DZP in aborting seizure activity [34]. When 
compared to intravenous DZP the mean time for controlling seizures was shorter for 
intravenous DZP but, as it happens for intranasal MDZ, the mean time from initiation of 
5 
 
treatment to seizure control was shorter with buccal MDZ [29]. Buccal MDZ is currently 
approved in the EU for the treatment of prolonged convulsive seizures in children and 
adolescents. It is available as Buccolam® by Shire Services and Epistatus® by Special 
Products Limited. Buccolam® contains MDZ Hydrochloride and comes in pre-filled oral 
syringes while Epistatus® contains MDZ Maleate and comes in pre-filled syringes as well as 
a 5 ml (10 mg/ml) bottle with four syringes in the package. Suggested dosages range from 2.5 
mg for patients aged between 6 and 12 months to 10 mg in patients aged more than 10 years.  
No studies compared directly buccal and intranasal MDZ. An indirect comparison meta-
analysis suggested no difference in efficacy and in the occurrence of serious adverse events 
between the two transmucosal formulations of MDZ [35]. Despite the limitations of an 
indirect meta-analysis, similarities are easy to explain. In fact, it is the same compound and 
the two roots of administration are both transmucosal, with the same pros and cons. In fact, as 
well as with intranasal MDZ, buccal MDZ is limited by the potential risk of seizure 
recurrence given the short half-life. However, head-to-head comparisons are needed as well 
as studies in adults.  
 
4. Sublingual delivery 
 The sublingual delivery is another root of administration within the oral mucosal 
cavity. The buccal and sublingual roots are slightly different with the latter being considered 
more permeable and capable of producing an even more rapid onset of action [36] and this is 
based on the relative thickness and degree of keratinization of these tissues. In fact, although 
both of them are non-keratinized tissues, the sublingual mucosa is thinner than the buccal 
ones [36]. In this regard, it is important to point out that the drug should be administered in 
different areas of the oral cavity in the sublingual and buccal routes. Sublingual medications 
are given under the tongue while buccal medications should be placed towards the back of 
the mouth between the upper or lower molars and the cheek.  
Although the sublingual delivery has a very good bioavailability, the absorption can be very 
slow [37] and the administration always requires the cooperation of the patient (Table 2). It 
appears, therefore, evident that the sublingual delivery is not ideal for patients having a 
convulsive seizure and this is further supported by the only published randomised controlled 
trial in 436 children showing that sublingual LZP is less efficacious than rectal DZP in 
controlling seizures [38]. 
 
5. Intramuscular auto-injection 
 Although the intramuscular root cannot be considered innovative, the development of 
new devices for the auto-injection of BDZs represents a novel delivery method permitting a 
timely treatment of epileptic seizures. Both intramuscular LZP and DZP are absorbed slowly 
while intramuscular MDZ exhibits a faster absorption (Table 1). In addition, the use of LZP 
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in non-hospital settings is limited by the need to be refrigerated. For all these reasons, studies 
on the intramuscular root focused on DZP and MDZ. 
Interestingly, the first auto-injector device for DZP was developed by the U.S. Army in the 
early 1990s for the immediate treatment of soman-induced seizures [39]. A Phase I study 
investigating bioequivalence and dose proportionality showed that DZP 10 mg auto-injection 
in the anterolateral thigh was bioequivalent to DZP injected with a conventional syringe [40]. 
In addition, this study also suggested that the site of injection is important because the gluteus 
or the deltoid muscles may lead to inconsistent absorption. A specific device was developed 
by Pfizer and a double-blind, randomised, placebo-controlled Phase III study showed that 
DZP auto-injection is safe and easy to use with significant reduction in time to next seizure as 
compared to placebo but did not prevent hospitalisation or need for further medical care [41]. 
The open label extension study showed that 78% of injections resulted in no subsequent 
seizures or rescue during the post-dose follow-up period [42]. Head-to-head comparisons 
with buccal MDZ would be of great value. 
A few studies suggested that intramuscular MDZ is as effective as intravenous diazepam in 
the acute management of seizures in children [43,44] but data on safety and efficacy of the 
auto-injector device for MDZ come mainly from the RAMPART study [45–47]. This double-
blind, randomized, non-inferiority trial compared the efficacy of the intramuscular MDZ 
auto-injection with that of intravenous LZP for children and adults with epilepsy [46]. This 
study demonstrated that pre-hospital treatment with intramuscular MDZ was at least as 
effective as intravenous LZP with the advantage that intramuscular treatments can be given 
more quickly and reliably than intravenous treatments. A recent study showed similar figures 
in the paediatric population [47] but more that on the safety of the device and head-to-head 
comparisons are needed. 
 
6. Unconventional routes 
Historically, drug delivery has been an important research topic for clinical 
pharmacologists. Non-oral routes of administrations, apart from those already discussed, 
would include the skin and air ways (Table 4). It seems rather evident that transcutaneous 
administration is not particularly indicated in an emergency setting as the absorption is 
usually slow and unreliable. The implant of a device releasing BDZs subcutaneously may 
represent an interesting option but there is no data about such a technique. 
A few delivery methods for BDZ though an inhalation route were developed many years ago, 
the first one through an aerosol [48] and a second one through a dry powder for pulmonary 
absorption [49]. However, no further studies are available on these two methods. A single-
blind study from China investigated the effect of an aerosol of DZP and a mixture of Chinese 
herbs on epileptic auras showing a 90% response rate [50] but neither pharmacokinetic 
parameters were provided nor the concentration of DZP administered. This study was not 
subsequently replicated and did not lead to further controlled trials or the development of 
specific technologies. 
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Another potential route of administration would be the direct delivery in the central nervous 
system (CNS). A number of possible methods have been theorised (Table 4) and some of 
them are already available for some compounds other than BDZ [51]. For example, 
intrathecal baclofen is very well-known for the treatment of spasticity [52] but this route may 
not be ideal for antiepileptic drugs as the brain distribution is usually very limited. Local 
perfusion via an implanted catheter attached to a pump programmed to infuse medications 
after detection of a seizure may represent an interesting option and a proof-of-principal of this 
approach was already presented in an animal model of epilepsy 20 years ago [53]. However, 
this method is burdened by a number of potential limitations, such as the high risk of 
respiratory depression and infections. Drug wafers are another potential route for direct CNS 
delivery. They are made of a polymer matrix with interwoven drug, releasing the medication 
over a prolonged period of time from weeks to years. Although this approach may have a 
rational for chemotherapy in brain tumors [54], it is definitely not indicated for the delivery 
of BDZ in the acute management of seizures. 
 
7. Conclusions 
BDZs represent the first line treatment for the acute management of epileptic seizures. Rectal 
DZP and buccal MDZ are the only currently licensed formulations for BDZ apart from the 
usual oral and parental routes but both of them have disadvantages mainly related to 
unpredictable absorption. Data from the RAMPART study have clearly demonstrated the 
efficacy and safety of non-intravenous formulations of BDZ in the acute management of 
seizures and intramuscular MDZ showed to be as effective as intravenous DZP. A number of 
alternative methods are currently under investigation and results are promising for the 
intranasal delivery and the intramuscular auto-injection device. Pre-hospital rescue plans 
should be individualised on the basis of patient’s needs, age, comorbidities potentially 
affecting absorption and distribution. Further studies are needed in order to establish efficacy 
and safety of these methods and to develop new potential delivery methods for BDZ in 
epilepsy.  
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Table 1. Pharmacokinetics of diazepam, lorazepam and midazolam (data derived 
from[5,6][11][10][37]). 
*absorption is faster in children and effective serum levels are reached in 5-10 min. 
# 83% with spray; 50% with injection solution 
 
 
  
 Diazepam Lorazepam Midazolam 
Volume 
distribution 
0.8-1.4  L/Kg 0.8-1.3 L/Kg 4.2-6.6 L/kg 
Elimination 
half-life 
40-60 h 8-20 h 1.5-2.5 h 
Clearance  0.5 mL/min/kg 0.7-1.2 mL/min/Kg 4-9 mL/min/kg 
Protein 
binding 
99% 90% 98% 
Bioavailability Intramuscular=100% 
Intranasal=70%-90% 
Rectal=80%-100% 
Intramuscular=100% 
Intranasal=77% 
Sublingual=94% 
Intramuscular = 91% 
Intranasal = 78%# 
Buccal = 74.5% 
T max after 
single dose 
Intramuscular=60min 
Intranasal=60-90 min 
Rectal = 30-75 min* 
Intramuscular=80min 
Intranasal=30 min 
Sublingual=erratic 
(up to 120 min)    
Intramuscular=20min 
Intranasal=10-15min 
Buccal=15-90min 
Active 
metabolite 
N-
desmethyldiazepam, 
oxazepam 
None  Alpha/hydroxy/midazolam 
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Table 2. Advantages and disadvantages of non-intravenous delivery methods for 
benzodiazepines. 
Delivery method Advantages Disadvantages 
Intranasal Ease to use 
Painless 
Avoid first pass metabolism 
Better bioavailability than 
rectal 
Socially acceptable 
Need for a high 
concentration to achieve 
ideal dosing volumes 
Mucosal health impacts on 
absorption 
Need to an ad hoc technology 
(i.e. atomizer) 
Buccal Ease to use 
Painless 
Avoid first pass metabolism 
Better bioavailability than 
oral 
No ad hoc technology needed 
Limited medications can be 
delivered in this fashion 
If swallowed convert to oral  
Sublingual Painless  
Ease to use 
Extremely easy to swallow 
Compliance is needed 
Intramuscular Traditinal and well-known 
method 
Many medications available 
for this delivery method 
Painfull 
Require training 
Variable onset of action and 
bioavailability 
Infection risk  
Rectal Minimal pain Variable bioavailability 
Slow onset of action 
(sometimes erratic) 
Socially unacceptable 
Limited medications 
available for this delivery 
method 
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Table 3. Summary of clinical studies on alternative non-intravenous delivery methods for benzodiazepines in the acute treatment of 
epileptic seizures. 
Route Drug Comparator Endpoint Pop N pts Results Adverse events Ref 
Intranasal LZP IM-PAR C C 160 =IM-PAR =IM-PAR [24] 
IV-LZP C C 141 =IV-LZP =IV-LZP [23] 
 
 
 
MDZ 
IV-DZP TC C 47 >IV-DZP =IV-DZP [21] 
R-DZP C C 45 >R-DZP >R-DZP [16] 
IV-DZP TC C 51 =IV-DZP =IV-DZP [20] 
R-DZP TC C 358 =R-DZP =IV-DZP [22] 
IV-DZP TC C 125 >IV-DZP =IV-DZP [19] 
R-DZP TC C 46 >R-DZP <R-DZP [13] 
IV-DZP TC C 70 <IV-DZP =IV-DZP [18] 
R-DZP TC A 21 =R-DZP =R-DZP [14] 
R-DZP TC C 124 =R-DZP <R-DZP [15] 
Buccal  
 
MDZ 
 
R-DZP TC C 7 >R-DZP =R-DZP [30] 
R-DZP TC C 98 =R-DZP =R-DZP [31] 
R-DZP TC C 43 =R-DZP =R-DZP [32] 
R-DZP C C 177 >R-DZP =R-DZP [33] 
R-DZP C C 42 =R-DZP =R-DZP [26] 
IV-DZP C C 120 =IV-DZP =IV-DZP [29] 
Sublingual LZP R-DZP TC C 436 <R-DZP =R-DZP [38] 
Intramuscular auto-injection DZP Placebo C* C 234 >Placebo =Placebo [41] 
MDZ IV-LZP C C-A 448 =IV-LZP
#
 =IV-LZP
#
 [46] 
MDZ = midazolam; DZP = diazepam; LZP = lorazepam; PAR=paraldehyde; R = rectal; IV = intravenous; IN= intranasal; B= buccal; 
SL=sublingual; IM=intramuscular;  TC=time to cessation; C (in Endpoint) =cessation; Pop=population; Pts = patients; C (in Pop) = children; A 
= adults; > superior than; < inferior than; = equal to; *Delaying the next seizure or rescue; 
#
Non-inferiority trial  
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Table 4. Potential unconventional drug delivery methods for benzodiazepines. 
Skin Transcutaneous (patches) 
Subcutaneous (implants) 
Inhalers Aerosol  
Pulmonary inhalation 
Direct CNS delivery Intrathecal 
Local perfusion via implanted catheter 
Drug wafers 
CNS = central nervous system 
 
 
 
 
